Renal effects of long‐term lithium therapy, revisited.

Autor: Yazıcı, M. Kâzım, Özçelik Eroğlu, Elçin, Ertuğrul, Aygün, Anıl Yağcıoğlu, A. Elif, Ağaoğlu, Esen, Karahan, Sevilay, Eni, Nurhayat, Sağlam Aykut, Demet, Kavak, Özlem, Erdem, Yunus
Předmět:
Zdroj: Human Psychopharmacology: Clinical & Experimental; Mar2022, Vol. 37 Issue 2, p1-8, 8p
Abstrakt: Objective: The aim of this study was to investigate the effect of lithium treatment on renal function and to determine influencing factors. In addition, the utility of spot urine protein/creatinine ratio in detection of lithium induced nephropathy was also investigated. Methods: Serum concentrations of lithium, blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), and urinalysis including protein/creatinine ratio were measured in 375 patients using lithium. Results: Patients taking lithium for ≥8 years had higher BUN, creatinine levels, percentage of proteinuria, percentages of stage 2 and 3 chronic kidney disease (CKD); lower urine density and eGFR compared to patients taking lithium <8 years. Urine density was lower in groups with >0.8 and 0.6–0.8 mmol/L lithium level than <0.6 mmol/L. Predictors of CKD were serum level of lithium, dose of lithium, cumulative duration of lithium use, age at onset of illness, and caffeine consumption. Conclusions: Detrimental effects of lithium on renal functions were detected after lithium use for ≥8 years. Proteinuria measured by spot urine protein/creatinine ratio can be detected even when eGFR is >90 ml/min/1.73 m2. Spot urine protein/creatinine ratio, which is a cost‐effective and practical laboratory test, can be used to monitor lithium‐treated patients. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje